{
    "nct_id": "NCT04294810",
    "official_title": "A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC\n* No prior systemic treatment for metastatic NSCLC\n* High tumor tissue PD-L1 expression\n* Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\n* Adequate hematologic and end-organ function\n* For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known mutation in the EGFR gene or an ALK fusion oncogene\n* Symptomatic, untreated, or actively progressing central nervous system metastases\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis\n* Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Positive test result for human immunodeficiency virus (HIV)\n* Active hepatitis B or hepatitis C\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.",
    "miscellaneous_criteria": ""
}